Vivesto (VIVE) Q2 2025 earnings summary

Executive summary

• Clinical recruitment for Paccal Vet pilot study in dogs with splenic hemangiosarcoma reached target, enabling interim data reporting soon.

• Positive preclinical data for Cantrixil in hematological cancer models, showing reduced tumor growth and increased survival.

• Focus on expanding clinical studies in cats and ongoing business development for Apealea in China.

Financial highlights

• Net sales were 0 TSEK for both Q2 and the first half, unchanged year-over-year.

• Operating loss for Q2 was -9,739 TSEK, improved from -11,016 TSEK year-over-year; H1 operating loss was -18,327 TSEK, improved from -20,195 TSEK.

• Net loss for Q2 was -9,526 TSEK (vs. -10,362 TSEK); H1 net loss was -17,814 TSEK (vs. -18,783 TSEK).

• Cash and short-term investments at period end totaled 4,221 TSEK, down from 52,131 TSEK year-over-year.

• Solid equity ratio at 92% (91% last year); negative net debt.

Outlook and guidance

• Cash runway expected to last into Q1 2026, supported by a 10 MSEK credit facility from the main shareholder.

• Management actively evaluating further financing options and partnerships for long-term operations.

• Key milestones ahead include interim Paccal Vet data, further Cantrixil results, and potential new business agreements.